Inhibition of Glucagon Secretion

Advances in Pharmacology

Volumn 52, Issue , 2005, Pages 151-171

  Young, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; ANTIDIABETIC AGENT; GLUCAGON;

ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; HUMAN; METABOLISM; PANCREAS ISLET ALPHA CELL; PHYSIOLOGY; REVIEW; SECRETION;

AMYLOID; ANIMALS; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL;

EID: 33646161943     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(05)52008-8     Document Type: Review

References (69)

1. Argoud G.M., Schade D.S., and Eaton R.P. Insulin suppresses its own secretion in vivo. Diabetes 36 (1987) 959-962
2. Ashcroft F.M., and Ashcroft S.J.H. Mechanism of insulin secretion. In: Ashcroft F.M., and Ashcroft S.J.H. (Eds). "Insulin: Molecular Biology to Pathology" (1992), Oxford University Press, New York 97-150
3. Beaumont K., Kenney M.A., Young A.A., and Rink T.J. High affinity amylin binding sites in rat brain. Mol. Pharmacol. 44 (1993) 493-497
4. Bendayan M. Pathway of insulin in pancreatic tissue on its release by the B-cell. Am. J. Physiol. 264 (1993) G187-G194
5. Bonner-Weir S., and Orci L. New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 31 (1982) 883-889
6. Cobb J.E., Kassel D.B., Sugg E.E., Burkhart W., Geddie N., Stele A., and Anderegg R.J. Mercury in a commercial preparation of rat amylin. Pept. Res. 5 (1992) 161-164
7. Cody W.L., Giordani A.B., Werness S., Reily M.D., Bristol J.A., Zhu G., and Dudley D.T. Analysis of rat amylin amide from commercial sources: Identification of a mercury complex. Bioorg. Med. Chem. Lett. 1 (1991) 415-420
8. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 237 (1979) E214-E223
9. Dégano P., Silvestre R.A., Salas M., Peiró E., and Marco J. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul. Pept. 43 (1993) 91-96
10. Dobbs R., Sakurai H., Sasaki H., Faloona G., Valverde I., Baetens D., Orci L., and Unger R. Glucagon: Role in the hyperglycemia of diabetes mellitus. Science 187 (1975) 544-547
11. Fineman M., Kolterman O., Thompson R., and Koda J. Glucagon secretion in patients with type I diabetes was inhibited by the human amylin analogue, pramlintide. Diabet. Med. 14 (1997) S29
12. Fineman M., Kolterman O., Thompson R., and Koda J. The human amylin analogue pramlintide inhibited glucagon secretion in type I diabetic subjects. 79th Annual Meeting of the Endocrine Society, Program and Abstracts (1997) 472
13. Fineman M., Kolterman O., Thompson R., and Koda J. The human amylin analogue pramlintide inhibited glucagon secretion in type I diabetic subjects. Diabetes 40 (1997) 30A
14. Fineman M.S., Kolterman O.G., Thompson R.G., and Koda J.E. The human amylin analogue pramlintide inhibited glucagon secretion in type I diabetic subjects. Diabetologia 40 (1997) A355
15. Fineman M., Koda J., and Kolterman O. Subcutaneous administration of a human amylin analogue suppresses postprandial plasma glucagon concentrations in type I diabetic patients. Diabetes 47 (1998) A89
16. Fineman M., Organ K., and Kolterman O. The human amylin analogue pramlintide suppressed glucagon secretion in patients with type 2 diabetes. Diabetologia 41 (1998) A167
17. Gedulin B., Jodka C., Percy A., and Young A. Neutralizing antibody and the antagonist AC187 may inhibit glucagon secretion in rats. Diabetes 40 (1997) 238A
18. Gedulin B., Jodka C., and Young A. Pramlintide inhibits arginine-induced glucagon secretion in rats. Diabet. Med. 14 (1997) S26
19. Gedulin B., Jodka C., and Young A. Pramlintide inhibits arginine-induced glucagon secretion in rats. Diabet. Metab. 23 (1997) P051
20. Gedulin B., Jodka C., and Young A. Pramlintide inhibits arginine-induced glucagon secretion in rats. Diabetes und Stoffwechsel 6 (1997) 54
21. Gedulin B., Percy A., Jodka C., and Young A. Endogenous amylin inhibits glucagon secretion, as demonstrated by studies using neutralizing antibody and the antagonist AC187. Diabet. Med. 14 (1997) S18
22. Gedulin B., Percy A., Jodka C., and Young A. Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion. Diabetologia 40 suppl. 1 (1997) A300
23. Gedulin B.R., Rink T.J., and Young A.A. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46 (1997) 67-70
24. Gedulin B., Jodka C., Lawler R., and Young A. Concentration-response for pramlintide inhibition of arginine-induced glucagon secretion in rats. Programs and Abstracts: 80th Annual Meeting of the Endocrine Society (1998) 276
25. Holst J.J. Enteroglucagon. Annu Rev. Physiol. 59 (1997) 257-271
26. Inoue K., Hiramatsu S., Hisatomi A., Umeda F., and Nawata H. Effects of amylin on the release of insulin and glucagon from the perfused rat pancreas. Horm. Metab. Res. 25 (1993) 135-137
27. Jodka C., Parkes D., and Young A.A. Amylin inhibits arginine-stimulated but not hypoglycemia-stimulated glucagon secretion in anesthetized rats. Diabet. Res. Clin. Pract. 50 (2000) S392
28. Kawamori R., Shichiri M., Kikuchi M., Yamasaki Y., and Abe H. The mechanism of exaggerated glucagon response to arginine in diabetes mellitus. Diabet. Res. Clin. Pract. 1 (1985) 131-137
29. Lacy P.E., and Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16 (1967) 35-39
30. Lakey J.R., Warnock G.L., Ao Z., and Rajotte R.V. Bulk cryopreservation of isolated islets of Langerhans. Cell Transplant 5 (1996) 395-404
31. Leclercq-Meyer V., Marchand J., Leclercq R., and Malaisse W.J. Glucagon and insulin release by the in vitro perfused rat pancreas. Diabet. Metab. 2 (1976) 57-65
32. Lehman-deGaeta L.S., Willis A.C., Young A.A., Foot E.A., Albrecht E., Leighton B., Rink T.J., and Cooper G.J.S. Variability of chemically synthesized human amylin. Diabetes 40 (1991) 236A
33. Levetan C., Want L.L., Weyer C., Strobel S.A., Crean J., Wang Y., Maggs D.G., Kolterman O.G., Chandran M., Mudaliar S.R., and Henry R.R. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglycerides excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabet. Care 26 (2003) 1-8
34. Lindsey C.A., Faloona G.R., and Unger R.H. Plasma glucagon levels during rapid exsanguination with and without adrenergic blockade. Diabetes 24 (1975) 313-316
35. Maruyama H., Hisatomi A., Orci L., Grodsky G.M., and Unger R.H. Insulin within islets is a physiologic glucagon release inhibitor. J. Clin. Invest. 74 (1984) 2296-2299
36. Müller W.A., Faloona G.R., Aguilar-Parada E., and Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283 (1970) 109-115
37. Nyholm B., Moller N., Gravholt C.H., Orskov L., Mengel A., Bryan G., Moyses C., Alberti K.G., and Schmitz O. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996) 1083-1089
38. Nyholm B., Orskov L., Hove K., Gravholt C., Moller N., Alberti N., and Schmitz O. The amylin analogue pramlintide decreases post-prandial plasma glucose and glucagon in IDDM. Diabetes 46 (1997)
39. Nyholm B., Orskov L., Hove K.Y., Gravholt C.H., Moller N., Alberti K.G.M.M., and Schmitz O. The amylin analogue pramlintide decreases postprandial plasma glucose and glucagon in IDDM patients. Diabetologia 40 (1997) A46
40. Nyholm B., Orskov L., and Schmitz O. The amylin analogue pramlintide decreased post-prandial plasma glucose and glucagon in patients with type I diabetes. Diabet. Med. 14 (1997) S29
41. Nyholm B., Orskov L., Hove K., Gravholt C., Moller N., Alberti K., Moyses C.K.O., and Schmitz O. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48 (1999) 935-941
42. Orskov L., Nyholm B., Hove K.Y., Gravholt C.H., Moller O., Kolterman O., Alberti K.G.M.M.A., and Schmitz O. Effects of the amylin analogue pramlintide on the glucose response to a glucagon challenge in IDDM. Diabetes 46 (1997) 155A
43. Orskov L., Nyholm B., Yde Hove K., Gravholt C.H., Moller N., and Schmitz O. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects. Diabet. Med. 16 (1999) 867-874
44. Parkes D., Chen K., Smith P., and Young A. Amylin does not suppress hypoglycemia-induced secretion of glucagon in rats. Diabetes 48 suppl. 1 (1999) A425
45. Pettersson M., and Ahren B. Insulin and glucagon secretion in rats: Effects of calcitonin gene-related peptide. Regul. Pept. 23 (1988) 37-50
46. Pieber T.R., Roitelman J., Lee Y., Luskey K.L., and Stein D.T. Direct plasma radioimmunoassay for rat amylin- (1-37): Concentrations with acquired and genetic obesity. Am. J. Physiol. 267 (1994) E156-E164
47. Raskin P., and Unger R.H. Glucagon and diabetes. Med. Clin. North Am. 62 (1978) 713-722
48. Raskin P., Fujita Y., and Unger R.H. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics. J. Clin. Invest. 56 (1975) 1132-1138
49. Raskin P., Aydin I., and Unger R.H. Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes 25 (1976) 227-229
50. Raskin P., Aydin I., Yamamoto T., and Unger R.H. Abnormal alpha cell function in human diabetes: The response to oral protein. Am. J. Med. 64 (1978) 988-997
51. Redecker P., Seipelt A., Jorns A., Bargsten G., and Grube D. The microanatomy of canine islets of Langerhans: Implications for intra-islet regulation. Anat. Embryol. (Berl.) 185 (1992) 131-141
52. Samols E., Bonner-Weir S., and Weir G.C. Intra-islet insulin-glucagon-somatostatin relationships. Clin. Endocrinol. Metab. 15 (1986) 33-58
53. Sgambato S., Passariello N., Giugliano D., Torella R., and D'Onofrio F. Effect of calcitonin on plasma glucose, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetic subjects. Acta Diabetol. Lat. 18 (1981) 235-241
54. Silvestre R.A., Miralles P., Moreno P., Villanueva M.L., and Marco J. Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat. Biochem. Biophys. Res. Commun. 134 (1986) 1291-1297
55. Silvestre R.A., Peiró E., Dégano P., Miralles P., and Marco J. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul. Pept. 31 (1990) 23-31
56. Silvestre R.A., Salas M., Rodriguez-Gallardo J., Garcia-Hermida O., Fontela T., and Marco J. Effect of (8-32). salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: Study in the perfused pancreas of the rat. Br. J. Pharmacol. 117 (1996) 347-350
57. Silvestre R.A., Rodríguez-Gallardo J., Gutiérrez E., García P., Egido E.M., and Marco J. Failure of amylin to directly affect glucagon release. Study in the perfused rat pancreas. Diabetologia 42 (1999) A146
58. Silvestre R.A., Rodriguez-Gallardo J., Jodka C., Parkes D.G., Pittner R.A., Young A.A., and Marco J. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am. J. Physiol. 280 (2001) E443-E449
59. Starke A., Keck E., Berger M., and Zimmermann H. Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus. Diabetologia 20 (1981) 547-552
60. Thompson R., and Kolterman O. Review of clinical data with pramlintide, a human amylin analogue. 79th Annual Meeting of the Endocrine Society, Program and Abstracts (1997) 473
61. Thompson R., Kolterman O., Peterson J., and Pearson L. Pramlintide reduced 24-hour glucose and serum fructosamine concentrations in people with type I diabetes mellitus. Can. J. Diabet. Care 21 (1997) 26
62. Unger R.H. Role of glucagon in the pathogenesis of diabetes: The status of the controversy. Metabolism 27 (1978) 1691-1709
63. Unger R.H. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28 (1985) 574-578
64. Unger R.H., and Foster D.W. Diabetes mellitus. In: Wilson J.D., and Foster D.W. (Eds). "Williams Textbook of Endocrinology". 8th ed (1992), W.B. Saunders, Philadelphia 1273-1275
65. Unger R.H., Aguilar-Parada E., Muller W.A., and Eisentraut A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49 (1970) 837-848
66. Weir G.C., and Bonner-Weir S. Islets of Langerhans-the puzzle of intraislet interactions and their relevance to diabetes. J. Clin. Invest. 85 (1990) 983-987
67. Young A.A., Wang M.W., and Cooper G.J.S. Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett. 291 (1991) 101-104
68. Young A.A., Jodka C.M., Green D.E., and Gedulin B.R. Inhibition of arginine-induced glucagon secretion by amylin in rats. Diabetes 44 (1995) 238A
69. Young A.A., Vine W., Gedulin B.R., Pittner R., Janes S., Gaeta L.S.L., Percy A., Moore C.X., Koda J.E., Rink T.J., and Beaumont K. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin. Drug Dev. Res. 37 (1996) 231-248